BACKGROUND:Naltrexone is approved for the treatment of alcohol dependence when used in conjunction with a psychosocial intervention. This study was undertaken to examine the impact of 3 types of psychosocial treatment combined with either naltrexone or placebo treatment on alcohol dependency over 24 weeks of treatment: (1) Cognitive-Behavioral Therapy (CBT) + medication clinic, (2) BRENDA (an intervention promoting pharmacotherapy) + medication clinic, and (3) a medication clinic model with limited therapeutic content. METHODS:Two hundred and forty alcohol-dependent subjects were enrolled in a 24-week double-blind placebo-controlled study of naltrexone (100 mg/d). Subjects were also randomly assigned to 1 of 3 psychosocial interventions. All patients were assessed for alcohol use, medication adherence, and adverse events at regularly scheduled research visits. RESULTS: There was a modest main treatment effect for the psychosocial condition favoring those subjects randomized to CBT. Intent-to-treat analyses suggested that there was no overall efficacy of naltrexone and no medication by psychosocial intervention interaction. There was a relatively low level of medication adherence (50% adhered) across conditions, and this was associated with poor outcome. CONCLUSIONS: Results from this 24-week treatment study demonstrate the importance of the psychosocial component in the treatment of alcohol dependence. Moreover, results demonstrate a substantial association between medication adherence and treatment outcomes. The findings suggest that further research is needed to determine the appropriate use of pharmacotherapy in maximizing treatment response.
RCT Entities:
BACKGROUND:Naltrexone is approved for the treatment of alcohol dependence when used in conjunction with a psychosocial intervention. This study was undertaken to examine the impact of 3 types of psychosocial treatment combined with either naltrexone or placebo treatment on alcohol dependency over 24 weeks of treatment: (1) Cognitive-Behavioral Therapy (CBT) + medication clinic, (2) BRENDA (an intervention promoting pharmacotherapy) + medication clinic, and (3) a medication clinic model with limited therapeutic content. METHODS: Two hundred and forty alcohol-dependent subjects were enrolled in a 24-week double-blind placebo-controlled study of naltrexone (100 mg/d). Subjects were also randomly assigned to 1 of 3 psychosocial interventions. All patients were assessed for alcohol use, medication adherence, and adverse events at regularly scheduled research visits. RESULTS: There was a modest main treatment effect for the psychosocial condition favoring those subjects randomized to CBT. Intent-to-treat analyses suggested that there was no overall efficacy of naltrexone and no medication by psychosocial intervention interaction. There was a relatively low level of medication adherence (50% adhered) across conditions, and this was associated with poor outcome. CONCLUSIONS: Results from this 24-week treatment study demonstrate the importance of the psychosocial component in the treatment of alcohol dependence. Moreover, results demonstrate a substantial association between medication adherence and treatment outcomes. The findings suggest that further research is needed to determine the appropriate use of pharmacotherapy in maximizing treatment response.
Authors: Bridget F Grant; Deborah A Dawson; Frederick S Stinson; S Patricia Chou; Mary C Dufour; Roger P Pickering Journal: Drug Alcohol Depend Date: 2004-06-11 Impact factor: 4.492
Authors: Elise M Weerts; Yu Kyeong Kim; Gary S Wand; Robert F Dannals; Jae Sung Lee; J James Frost; Mary E McCaul Journal: Neuropsychopharmacology Date: 2007-05-09 Impact factor: 7.853
Authors: Jon Morgenstern; Alexis N Kuerbis; Andrew C Chen; Christopher W Kahler; Donald A Bux; Henry R Kranzler Journal: J Consult Clin Psychol Date: 2012-05-21
Authors: Raye Z Litten; I-Jen P Castle; Daniel Falk; Megan Ryan; Joanne Fertig; Chiung M Chen; Hsiao-ye Yi Journal: Alcohol Clin Exp Res Date: 2013-07-24 Impact factor: 3.455
Authors: Robert L Stout; Jordan M Braciszewski; Meenakshi Sabina Subbaraman; Henry R Kranzler; Stephanie S O'Malley; Daniel Falk Journal: Addiction Date: 2014-09-12 Impact factor: 6.526
Authors: Jennifer G Plebani; Carlos F Tirado; Helen M Pettinati; Kyle M Kampman; Joseph R Volpicelli; David W Oslin Journal: Addict Behav Date: 2009-09-10 Impact factor: 3.913
Authors: Natalya C Maisel; Janet C Blodgett; Paula L Wilbourne; Keith Humphreys; John W Finney Journal: Addiction Date: 2012-10-17 Impact factor: 6.526
Authors: Richard Longabaugh; Philip W Wirtz; Suzy Bird Gulliver; Dena Davidson Journal: Psychopharmacology (Berl) Date: 2009-07-29 Impact factor: 4.530